elotuzumab,dexamethasone,daratumumab,bortezomib,lenalidomide,carfilzomib
abbvie,janssen,amgen,bms,takeda
['s1211', 'great work', 'krd', 'mmsm', 'griffin']
1/ #ash22 great work by ! optimal induction in high-risk #mmsm pts remains unknown (just not elo-vrd per s1211). retrospective data: krd beat vrd, perhaps via mrd-neg. (d-vrd hasn't beaten vrd in griffin among high-risk, likely due to small n). 
Asst Professor @UWMedicine @fredhutch, s/p @PennIMResidents ??@UCSFCancer training. Myeloma #MMsm #cellphonesandcelltherapies ????

COI: https://t.co/3Uuojuio6R